PLSE · Pulse Biosciences, Inc.

Pulse Biosciences’ Q1 2026 results reflect continued heavy investment in clinical development—particularly the NANOPULSE-AF and NANOCLAMP-AF trials—with R&D expenses totaling $12.6M and SG&A at $6.6M, driving a $18.6M GAAP net loss. Revenue remained flat at $0.4M, exclusively from nPulse Vybrance capital and disposables, underscoring that commercialization remains nascent and not yet a material contributor. The $14.6M operating cash outflow aligns with prior quarters, confirming sustained burn consistent with late-stage clinical execution. Critically, the acceleration of NANOPULSE-AF enrollment to early-Q4 2026—based on first-patient treatments in early April and high investigator enthusiasm—signals improved trial momentum and potential de-risking of the U.S. IDE pathway. This is reinforced by leadership additions: Liane Teplitsky as COO brings electrophysiology-specific operational expertise, and Dr. Kenigsberg’s full-time CMO role strengthens clinical strategy. While cash stands at $68.3M—sufficient to fund operations into 2027 per disclosed runway assumptions—the $1.6M YoY increase in GAAP net loss and $4.7M YoY rise in Non-GAAP expenses highlight intensifying near-term investment pressure. Management’s commentary explicitly ties strategic focus to electrophysiology and landmark clinical data—including 100% procedural success at 6 months in the European feasibility study—as justification for prioritizing catheter development. With no forward revenue or margin guidance provided, investor attention remains squarely on clinical execution timelines, regulatory progress, and cash sustainability through anticipated 2027 PMA submission milestones.